Stocks That Hit 52-Week Lows On Tuesday
Tuesday's morning session saw 84 companies set new 52-week lows.
Morgan Stanley Maintains Equal-Weight on ADC Therapeutics, Lowers Price Target to $5
Morgan Stanley analyst Matthew Harrison maintains ADC Therapeutics (NYSE:ADCT) with a Equal-Weight and lowers the price target from $7 to $5.
Reported Late Wednesday, IntoCell Enters Into Development And License Option Agreement With ADC Therapeutics
IntoCell today announced the signing of a Material Transfer Agreement (MTA) with option to license with ADC Therapeutics SA (NYSE:ADCT).
Under the agreement, IntoCell, a South Korean biotech developing novel antibody
ADC Therapeutics And Sobi Announce European Commission Approval Of ZYNLONTA For The Treatment Of Relapsed Or Refractory Diffuse Large B-Cell Lymphoma; Approval Triggers $50M Milestone Payment To ADC Therapeutics
Approval triggers $50 million milestone payment to ADC Therapeutics
ADC Therapeutics SA (NYSE:ADCT) and Swedish Orphan Biovitrum AB (Sobi®) today announced the European Commission (EC) has granted
ADC Therapeutics Gets European Commission Approval Of Zynlonta For The Treatment Of Relapsed Or Refractory Diffuse Large B-cell Lymphoma’
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2022)9955&lang=en
Biocytogen Late Sunday Announced Co. Entered Into Antibody Agreement With ADC Therapeutics
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", HKEX: 02315) today announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC